Earnings calendar/AQST
Aquestive Therapeutics, Inc. (AQST)
Pre-earnings consensus targets and post-earnings beat/miss — standardized metrics from the earnings calendar. No narrative, no price targets.
Pre-earnings
Consensus targets for the next print, plus how the business has been running.
Next report
Nov 4, 2026
Consensus estimate row
EPS target
$-0.11
Street estimate
Revenue target
$11.4M
Street estimate
Trailing EPS (avg 4Q)
$-0.16
Beat rate last 4: 25%
Latest EPS YoY
-28.6%
vs 2025-08-11
Latest revenue YoY
+38.1%
How results look so far
Trailing revenue (avg 4Q)
$13.5M
Printed quarters
EPS beat rate (4Q)
25%
Share of quarters that beat EPS est.
Post-earnings
Did the company hit the target? Actual vs estimate and surprise.
Last print
Aug 11, 2026
EPS miss
EPS actual / est
$-0.18 / $-0.10
-71.4%
Revenue actual / est
$13.8M / $11.4M
+21.0%
Result
Below target
Based on EPS vs consensus
Earnings history
Estimate vs actual and surprise % by print date
| Date | EPS est | EPS act | EPS surprise | Rev est | Rev act | Rev surprise |
|---|---|---|---|---|---|---|
| 11/4/2026upcoming | $-0.11 | Pending | — | $11.4M | Pending | — |
| 8/11/2026 | $-0.10 | $-0.18 | -71.4% | $11.4M | $13.8M | +21.0% |
| 5/13/2026 | $-0.14 | $-0.07 | +50.0% | $10.9M | $14.4M | +32.6% |
| 5/11/2026upcoming | $-0.14 | Pending | — | $10.9M | Pending | — |
| 3/4/2026 | $-0.13 | $-0.26 | -100.0% | $13.3M | $13.0M | -2.0% |
| 11/5/2025 | $-0.11 | $-0.14 | -27.3% | $12.9M | $12.8M | -1.1% |
| 8/11/2025 | $-0.18 | $-0.14 | +22.2% | $12.2M | $10.0M | -18.0% |
| 5/12/2025 | $-0.17 | $-0.24 | -41.2% | $12.2M | $8.7M | -28.7% |
| 3/5/2025 | $-0.14 | $-0.19 | -35.7% | $13.1M | $11.9M | -9.5% |
| 11/4/2024 | $-0.12 | $-0.13 | -8.3% | $13.1M | $13.5M | +3.2% |
| 8/6/2024 | $-0.11 | $-0.03 | +72.7% | $12.4M | $20.1M | +62.4% |
| 5/7/2024 | $-0.09 | $-0.17 | -88.9% | $12.3M | $12.1M | -1.7% |
| 3/5/2024 | $-0.08 | $-0.12 | -50.0% | $11.6M | $13.2M | +13.6% |
| 11/6/2023 | $-0.11 | $-0.03 | +72.7% | $11.6M | $13.0M | +11.8% |
| 8/7/2023 | $-0.11 | $-0.10 | +9.1% | $11.0M | $13.2M | +20.3% |
| 5/2/2023 | $-0.10 | $0.11 | +210.0% | $9.9M | $11.1M | +12.2% |
| 3/7/2023 | $-0.21 | $-0.23 | -9.5% | $10.4M | $10.7M | +2.5% |
| 11/1/2022 | $-0.30 | $-0.23 | +23.3% | $11.0M | $11.5M | +4.2% |
| 8/2/2022 | $-0.41 | $-0.36 | +12.2% | $10.6M | $13.3M | +25.5% |
| 5/3/2022 | $-0.45 | $-0.32 | +28.9% | $10.1M | $12.3M | +21.1% |
| 3/8/2022 | $-0.47 | $-0.38 | +19.1% | $9.4M | $11.1M | +18.3% |
| 11/2/2021 | $-0.40 | $-0.37 | +7.5% | $11.0M | $13.3M | +20.7% |
| 8/3/2021 | $-0.42 | $-0.33 | +21.4% | $15.3M | $15.3M | 0.0% |
| 5/4/2021 | $-0.44 | $-0.41 | +6.8% | $6.2M | $11.1M | +78.2% |
| 3/9/2021 | $-0.46 | $-0.60 | -30.4% | — | $7.1M | — |
| 11/4/2020 | $-0.50 | $-0.49 | +2.0% | $7.8M | $8.3M | +6.5% |
| 8/4/2020 | $-0.43 | $-0.07 | +83.7% | $133.1M | $21.7M | -83.7% |
| 5/5/2020 | $-0.52 | $-0.49 | +5.8% | $8.4M | $8.8M | +4.3% |
| 3/11/2020 | $-0.45 | $-0.48 | -6.7% | $13.3M | $16.4M | +23.1% |
| 11/5/2019 | $-0.78 | $-0.54 | +30.8% | $11.6M | $12.4M | +7.2% |
| 8/6/2019 | $-0.67 | $-0.82 | -22.4% | $8.4M | $11.1M | +32.3% |
| 5/8/2019 | $-0.49 | $-0.59 | -20.4% | $10.7M | $12.6M | +18.0% |
| 3/14/2019 | $-0.91 | $-0.56 | +38.5% | $15.3M | $16.8M | +9.8% |
| 11/6/2018 | $-0.49 | $-0.49 | 0.0% | $8.9M | $13.3M | +48.8% |
| 9/4/2018 | $-0.24 | $-1.90 | -691.7% | — | $13.9M | — |
| 7/26/2018 | — | $0.20 | — | — | $23.4M | — |
| 12/31/2017 | — | $-0.50 | — | — | $12.2M | — |
| 9/30/2017 | — | $0.42 | — | — | $27.1M | — |
| 6/30/2017 | — | $-0.29 | — | — | $11.1M | — |
| 3/31/2017 | — | $-0.07 | — | — | $16.4M | — |